Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med (2016) 3.71

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis (2014) 3.69

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31

Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med (2015) 1.65

CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev (2013) 1.58

Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition. HIV Med (2013) 1.57

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol (2014) 1.44

Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database. PLoS One (2016) 1.38

Repeat HIV-testing is associated with an increase in behavioral risk among men who have sex with men: a cohort study. BMC Med (2015) 1.34

When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med (2013) 1.30

Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open (2013) 1.29

Using HIV networks to inform real time prevention interventions. PLoS One (2014) 1.29

Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men. Clin Infect Dis (2015) 1.28

A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology (2013) 1.24

Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms. Clin Infect Dis (2015) 1.23

How can we better identify early HIV infections? Curr Opin HIV AIDS (2015) 1.18

Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis (2013) 1.13

Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening. Emerg Infect Dis (2016) 1.09

Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev (2013) 1.08

Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One (2013) 1.07

Risk Factors for Acute and Early HIV Infection Among Men Who Have Sex With Men (MSM) in San Diego, 2008 to 2014: A Cohort Study. Medicine (Baltimore) (2015) 1.05

Immunology of pediatric HIV infection. Immunol Rev (2013) 1.02

The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr (2013) 0.98

Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population. PLoS One (2014) 0.98

Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. J Int AIDS Soc (2014) 0.97

Antiretroviral therapy in early HIV infection. N Engl J Med (2013) 0.95

Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog (2014) 0.95

Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol (2014) 0.92

Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release. J Virol (2014) 0.91

Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol (2013) 0.90

HIV Transmission Networks in the San Diego-Tijuana Border Region. EBioMedicine (2015) 0.90

Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies. Clin Transl Immunology (2014) 0.89

Barriers to HIV testing and characteristics associated with never testing among gay and bisexual men attending sexual health clinics in Sydney. J Int AIDS Soc (2015) 0.88

Brain alterations within the first 100 days of HIV infection. Ann Clin Transl Neurol (2014) 0.87

Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection. J Virol (2013) 0.86

Can early therapy reduce inflammation? Curr Opin HIV AIDS (2014) 0.86

Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. AIDS (2014) 0.86

Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort. BMC Immunol (2013) 0.84

Rapid HIV Testing Is Highly Acceptable and Preferred among High-Risk Gay And Bisexual Men after Implementation in Sydney Sexual Health Clinics. PLoS One (2015) 0.84

Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California. Ann Epidemiol (2014) 0.84

Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use. J Gerontol A Biol Sci Med Sci (2015) 0.83

Determinants of HIV-induced brain changes in three different periods of the early clinical course: A data mining analysis. Neuroimage Clin (2015) 0.83

Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol (2016) 0.82

No evidence of posttreatment control after early initiation of antiretroviral therapy. AIDS (2015) 0.82

Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS (2015) 0.82

Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS (2016) 0.82

The HIV treatment cascade in acutely infected people: informing global guidelines. Curr Opin HIV AIDS (2015) 0.81

Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. J Med Primatol (2013) 0.81

Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment. Clin Infect Dis (2016) 0.81

CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. Medicine (Baltimore) (2016) 0.81

Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help? Curr Opin HIV AIDS (2015) 0.80

Community HIV-1 drug resistance is associated with transmitted drug resistance. HIV Med (2014) 0.80

HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs. J Immunol (2014) 0.79

Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. Pediatrics (2014) 0.79

Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests. PLoS One (2014) 0.79

Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology (2015) 0.79

Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. J Acquir Immune Defic Syndr (2016) 0.79

HIV-1 testing of young febrile adults seeking care for fever in sub-Sahara Africa. Int Health (2014) 0.79

Impact of early cART in the gut during acute HIV infection. JCI Insight (2016) 0.79

What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan. PLoS One (2015) 0.79

Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis. Sci Rep (2016) 0.78

The natural history of HIV infection. Curr Opin HIV AIDS (2013) 0.78

Using HIV Sequence and Epidemiologic Data to Assess the Effect of Self-referral Testing for Acute HIV Infection on Incident Diagnoses in San Diego, California. Clin Infect Dis (2016) 0.78

Routine Screening for HIV Infection in Medical Care Settings: A Decade of Progress and Next Opportunities. Public Health Rep (2016) 0.78

Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum. J Neurovirol (2014) 0.78

Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013. J Acquir Immune Defic Syndr (2016) 0.78

Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. J Int AIDS Soc (2017) 0.77

A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression. PLoS One (2014) 0.77

Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. AIDS (2017) 0.77

The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS (2016) 0.77

Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. PLoS One (2016) 0.77

Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin. BMC Infect Dis (2016) 0.77

Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection. AIDS (2016) 0.77

Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. J Immunol (2015) 0.77

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. J Acquir Immune Defic Syndr (2016) 0.77

Neurobehavioral Disturbances During Acute and Early HIV Infection. Cogn Behav Neurol (2016) 0.77

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. PLoS One (2015) 0.76

Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells. PLoS One (2015) 0.76

Interaction Effects between HIV and Aging on Selective Neurocognitive Impairment. J Neuroimmune Pharmacol (2017) 0.75

Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. AIDS (2016) 0.75

Enrolment trends in a comprehensive HIV programme in rural north-central Nigeria: improved care indices, but declining quality of clinical data over time. Pathog Glob Health (2015) 0.75

Concurrency and HIV transmission network characteristics among MSM with recent HIV infection. AIDS (2016) 0.75

How can we detect HIV during the acute or primary stage of infection? Expert Rev Mol Diagn (2016) 0.75

Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria. PLoS One (2015) 0.75

Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients. BMC Med Res Methodol (2016) 0.75

HIV Trafficking Between Blood and Semen During Early Untreated HIV Infection. J Acquir Immune Defic Syndr (2017) 0.75

Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. Immunol Lett (2014) 0.75

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. Infect Dis Ther (2016) 0.75

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption? BMC Infect Dis (2015) 0.75

A case cluster demonstrating the relationship between HLA concordance and virologic and disease outcomes in human immunodeficiency virus infection. Virology (2013) 0.75

When to start ART in Africa--primarily guided by RCTs or patient autonomy? J Int AIDS Soc (2013) 0.75

Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. Clin Infect Dis (2015) 0.75

Knowledge and awareness of acute human immunodeficiency virus infection among mobile app-using men who have sex with men: a missed public health opportunity. Open Forum Infect Dis (2015) 0.75

Early Antiretroviral Therapy is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. PLoS Pathog (2017) 0.75

Colorectal Disorders in Acute Human Immunodeficiency Virus Infection: A Case Series. Open Forum Infect Dis (2016) 0.75

Virological blips and predictors of post treatment viral control after stopping ART started in Primary HIV infection. J Acquir Immune Defic Syndr (2016) 0.75

Strengthening healthcare providers' skills to improve HIV services for MSM in Kenya. AIDS (2015) 0.75

Antiretroviral therapy: when to start. Infect Dis Clin North Am (2014) 0.75

Never too early for the opportunists! BMJ Case Rep (2013) 0.75

Clinical trials provide the evidence critical for patient empowerment. J Int AIDS Soc (2013) 0.75

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76

Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36

Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66

HIV infection and the gastrointestinal immune system. Mucosal Immunol (2008) 3.14

Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr (2003) 3.14

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88

HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep (2012) 2.71

T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med (1993) 2.50

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30

Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27

Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood (2012) 2.20

Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog (2012) 1.91

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis (2010) 1.63

Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J Infect Dis (1988) 1.52

CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis (2011) 1.40

Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol (2012) 1.39

Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med (2010) 1.38

Immunological changes in primary HIV-1 infection. AIDS (1990) 1.30

Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis (1999) 1.21

Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl. AIDS (2012) 1.09

A review on peripheral blood CD4+ T lymphocyte counts in healthy adult Indians. Indian J Med Res (2010) 0.97

The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00

Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03

Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20

Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe (2008) 4.55

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45

Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74

Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66

2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66

Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58

Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53

Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52

CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20

Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04

CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94

Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91

Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82

Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79

Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54

A 12-year, prospective study of extraocular muscle imaging in complex strabismus. J AAPOS (2002) 2.52

Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol (2006) 2.48

Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem (2002) 2.41

Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A (2008) 2.38

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33

HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A (2002) 2.31

Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26

HIV superinfection. J Infect Dis (2005) 2.20

Whither or wither microbicides? Science (2008) 2.17

Magnetic resonance imaging evidence for widespread orbital dysinnervation in congenital fibrosis of extraocular muscles due to mutations in KIF21A. Invest Ophthalmol Vis Sci (2005) 2.12

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07

Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS (2003) 2.05

Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04

Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis (2012) 1.99

Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer (2003) 1.96

Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92

NOX enzymes as novel targets for drug development. Semin Immunopathol (2008) 1.90

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83

A public health model for the molecular surveillance of HIV transmission in San Diego, California. AIDS (2009) 1.81

Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal (2009) 1.80

Active pulleys: magnetic resonance imaging of rectus muscle paths in tertiary gazes. Invest Ophthalmol Vis Sci (2002) 1.79

Serosorting can potentially increase HIV transmissions. AIDS (2007) 1.78

A strong signature of balancing selection in the 5' cis-regulatory region of CCR5. Proc Natl Acad Sci U S A (2002) 1.78

Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77

The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76

Magnetic resonance imaging evidence for widespread orbital dysinnervation in dominant Duane's retraction syndrome linked to the DURS2 locus. Invest Ophthalmol Vis Sci (2007) 1.75

Transmission behaviors of recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr (2006) 1.73

Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72

Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther (2012) 1.71

Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis (2010) 1.71

HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One (2008) 1.69